John G. Aunins has sold MCRB and made no open-market buys since Mar 2016
CTO and EVP at Seres Therapeutics, Inc.
SEC CIK 0001643756 · Filings on SEC.gov ↗
$0Bought
$3.2MSold
NoneLast buy
Every filing
14 filings since Mar 2016, newest first
MCRBSell
Seres Therapeutics, Inc.
CTO and EVP
$91K−14.0%Dec 19
MCRBSell
Seres Therapeutics, Inc.
Insider
$118K−14.0%Nov 19
MCRBSell
Seres Therapeutics, Inc.
Insider
$85K−12.0%Oct 16
MCRBSell
Seres Therapeutics, Inc.
Insider
$327K−27.0%Sep 19
MCRBSell
Seres Therapeutics, Inc.
CTO and EVP
$116K−8.0%Jul 18
MCRBSell
Seres Therapeutics, Inc.
CTO and EVP
$122K−8.0%Jun 18
MCRBSell
Seres Therapeutics, Inc.
CTO and EVP
$108K−7.0%Apr 26
MCRBSell
Seres Therapeutics, Inc.
CTO and EVP
$595K−25.0%Aug 31
MCRBSell
Seres Therapeutics, Inc.
CTO and EVP
$102K−5.0%Aug 30
MCRBSell
Seres Therapeutics, Inc.
CTO and EVP
$324K−4.0%Jul 29
MCRBSell
Seres Therapeutics, Inc.
CTO and EVP
$321K−4.0%Jul 26
MCRBSell
Seres Therapeutics, Inc.
CTO and EVP
$256K−22.0%Jun 29
MCRBSell
Seres Therapeutics, Inc.
CTO and EVP
$421K−25.0%Jun 2
MCRBSell
Seres Therapeutics, Inc.
CTO and EVP
$224K−11.0%Mar 29
Filings come from SEC EDGAR. Not investment advice.